DRR168535
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.490
- PROTEIN_SECRETION+0.470
- MTORC1_SIGNALING+0.420
- ANDROGEN_RESPONSE+0.370
- MYC_TARGETS_V1+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.370
- SPERMATOGENESIS+0.350
- PANCREAS_BETA_CELLS+0.310
- CHOLESTEROL_HOMEOSTASIS+0.300
Top 10 suppressed
- ANGIOGENESIS-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- WNT_BETA_CATENIN_SIGNALING-0.350
- HEDGEHOG_SIGNALING-0.340
- P53_PATHWAY-0.300
- NOTCH_SIGNALING-0.250
- COAGULATION-0.220
- APICAL_JUNCTION-0.210
- TGF_BETA_SIGNALING-0.210
- DNA_REPAIR-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A0JD-01A-11R-A056-07 | — | C | 0.795 |
| 2 | SRR1797278 | — | cohortSC | 0.794 |
| 3 | DRR168588 | — | — | 0.785 |
| 4 | SRR11296733 | — | — | 0.746 |
| 5 | TCGA-BH-A18U-01A-21R-A12D-07 | — | C | 0.744 |
| 6 | SRR1797281 | — | cohortSC | 0.739 |
| 7 | SRR2932839 | — | — | 0.737 |
| 8 | feccc57b-a987-4dd7-babf-1a8982bd64cc | — | — | 0.735 |
| 9 | SRR1516045 | — | — | 0.731 |
| 10 | TCGA-FD-A6TE-01A-12R-A33J-07 | — | — | 0.731 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |